Loading
The PD-1 antibody cemiplimab lengthened survival compared with single-agent chemotherapy in recurrent cervical cancer after platinum, regardless of PD-L1 expression, the first immunotherapy to show a survival benefit in this disease.
Phase 3 trial of 608 patients with recurrent cervical cancer progressing after first-line platinum chemotherapy randomised to cemiplimab or investigator's choice single-agent chemotherapy, enrolled irrespective of PD-L1 status.
Median overall survival was 12.0 versus 8.5 months (hazard ratio 0.69) overall and 11.1 versus 8.8 months in squamous cell carcinoma; response was 16.4 versus 6.3 percent, and benefit was seen across PD-L1 levels.
Cemiplimab is an option for second-line cervical cancer in patients who have not had immunotherapy, though most now receive pembrolizumab first line, moving cemiplimab later or out of sequence.
Shares Krishnansu S. Tewari, Recurrent or metastatic cervical cancer, New England Journal of Medicine.
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.